Supplements and Featured Publications
Unpacking Pivotal Data Updates in Metastatic Breast Cancer Management
Sponsored in part by AstraZeneca and Daiichi Sankyo. Content produced and independently developed by OncLive.
Focus on Pathways: SERMS in Metastatic Breast Cancer
Top 8 Trials From 2021 in Breast Cancer
The Top 2021 Abstracts in Breast Cancer publication provides expert insights on groundbreaking abstracts in breast cancer, with a focus on HER2-positive breast cancer treatment that were presented at medical meetings throughout 2021.
Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®
SABCS 2021: Updates in HER2+ Breast Cancer
The SABCS 2021: Updates in HER2+ Breast Cancer publication provides expert insights on clinical news in HER2-positive breast cancer treatment from the 2021 San Antonio Breast Cancer Symposium.
Funding From Daiichi Sankyo/Content Developed Independently by OncLive
2021 Year in Review: HER2+ Breast Cancer
The 2021 Year in Review: HER2+ Breast Cancer is the digital version of a print publication encompasses some of the biggest data that have read out in HER2-positive breast cancer in 2021, along with expert insights in article and video format.
2021 ESMO Congress: Breast Cancer
The 2021 ESMO Congress priority report focuses on updates in breast cancer presented at the virtual conference, which was held September 16 to 21, 2021.
Defining Value for the Treatment of Brain Metastases in Metastatic HER2-Positive Breast Cancer
Updates in ESR1-Mutant Breast Cancer
The Role of Chemotherapy and Novel Combinations in Triple Negative Breast Cancer
